SCHEMBL792224

SCHEMBL792224

O=C1COc2c(cccc2N2CCN(CCCCNS(=O)(=O)c3ccc(Cl)s3)CC2)N1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
DRD2 P14416 12/20 0.50
HTR1A P08908 15/20 0.46
HTR1D P28221 2/20 0.46
HTR1B P28222 2/20 0.46
SLC6A4 P31645 2/20 0.46
KCNH2 Q12809 2/20 0.46
DRD4 P21917 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
DRD3 P35462 1/20 0.44
HTR2A P28223 11/20 0.43
HTR7 P34969 9/20 0.43
HTR6 P50406 9/20 0.43
HTR2B P41595 1/20 0.43
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792939 0.86 DRD2 (0.52) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL792651 0.85 HTR7 (0.50) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL791718 0.85 DRD2 (0.53) DRD2HTR1ADRD4ADRA1DADRA1A
SCHEMBL793139 0.84 DRD2 (0.52) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL792874 0.83 DRD2 (0.51) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL791671 0.83 HTR7 (0.49) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL792873 0.82 HTR1A (0.61) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL793262 0.82 KMT2A (0.58) KMT2ADRD2HTR1ADRD3HTR2A
SCHEMBL792868 0.82 HTR1A (0.50) DRD2HTR1AHTR1DHTR1BSLC6A4
SCHEMBL792444 0.81 DRD2 (0.54) DRD2HTR1AHTR1DHTR1BSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP claimed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US claimed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO claimed
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2014-11-13 US disclosed
US-8822517-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z O.O. (PL) 2014-09-02 US disclosed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP disclosed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US disclosed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS KMT2A 1521/4885DRD2 3216/4885HTR1A 1354/4885
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS KMT2A 1521/4885DRD2 3216/4885HTR1A 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.